Acquisition Completion of Triad Life Sciences Inc

RNS Number : 6368E

ConvaTec Group PLC

14 March 2022

 

14 March 2022

ConvaTec Group completes acquisition of Triad Life Sciences Inc

Further to the announcement of 28 January 2022, ConvaTec Group Plc (CTEC:LON) is pleased to announce that it has completed the acquisition of Triad Life Sciences Inc ('Triad').

The Triad team, current portfolio and product pipeline will now transition to ConvaTec's Advanced Wound Care (AWC) business and be known as ConvaTec Advanced Tissue Technologies .

***

Contacts

Analysts & Investors	Kate Postans, Vice President of Investor Relations & Corporate Communications	[phone] [e-mail]
Media	Buchanan: Charles Ryland / Chris Lane	[phone]

About ConvaTec

ConvaTec is a FTSE 250 global medical products and technologies company focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. We have more than 10,000 colleagues and sell our products and services in over 100 countries. Our vision is Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. Group revenues in 2021 were over $2 billion. To learn more about ConvaTec, please visit  http://www.convatecgroup.com  

 

END

 

 

ACQGPUQWWUPPUQC